Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | THPO | P40225 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507858 | 0.78 | APP (0.61) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL9146168 | 0.78 | APP (0.61) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL5507856 | 0.78 | APP (0.61) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL3821137 | 0.75 | APP (0.50) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL25367784 | 0.75 | KCNH2 (0.44) | KCNH2GRM5HSD17B10 | |
| SCHEMBL840229 | 0.74 | APP (0.55) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL136424 | 0.74 | APP (0.55) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL8696089 | 0.74 | APP (0.55) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL6234793 | 0.74 | APP (0.55) | APPNPC1RAB9AMTORMAPT | |
| SCHEMBL6244468 | 0.74 | APP (0.55) | APPNPC1RAB9AMTORMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0161877-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1991-05-29 | — | — | EP | claimed |
| EP-3098226-B1 | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-10100070-B2 | Borate-based base generator, and base-reactive composition comprising such base generator | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3098226-A1 | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | Wako Pure Chemical Industries, Ltd. (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160340374-A1 | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-0387196-B1 | Complexes with optically active ligands, process for their preparation and their use | CIBA GEIGY AG (CH) | 1995-05-03 | — | — | EP | disclosed |
| EP-0254685-B1 | Complexes with optically active sugar ligands, process for their preparation and their use | CIBA GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5047557-A | Complexes having optically active ligands, a process for their preparation and their use | CIBA-GEIGY CORPORATION (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0161877-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1991-05-29 | — | — | EP | disclosed |
| EP-0387196-A1 | Complexes with optically active ligands, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1990-09-12 | — | — | EP | disclosed |
| US-4914196-A | CHIRAL REACTANTS FOR ALDEHYDES, KETONES, N-SUBSTITUTED IMINES | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4845100-A | WITH HYPOTENSIVE AND ANTIINFLAMMATORY ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4826965-A | Metal complexes containing optically active sugar ligands, a process for their preparation and their use as chiral reactants for synthesis of alcohols and amines | CIBA-GEIGY CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0254685-A2 | Complexes with optically active sugar ligands, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1988-01-27 | — | — | EP | disclosed |
| EP-0202760-A2 | Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100070-B2 | Borate-based base generator, and base-reactive composition comprising such base generator | BLM, HPRT1, BROX | APP 2287/4885NPC1 3908/4885RAB9A 579/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | APP 4602/4885NPC1 3130/4885RAB9A 3153/4885 |
| US-20160340374-A1 | BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR | ENPP3, GNG2, ENPP1 | APP 3912/4885NPC1 4267/4885RAB9A 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.